ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 6|浏览15

暂无评分

摘要

TPS177Background: 177Lu‐PSMA‐617 (LuPSMA) is a novel radionuclide with promising activity and tolerability in metastatic, castration-resistant prostate cancer (mCRPC). Pre-clinical studies have sho...

查看译文

关键词

Enzalutamide,Prostate cancer,Tolerability,Oncology,Medicine,Castration resistant,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要